The Human Upgrade: Biohacking for Longevity & Performance

10-Minute Weekly Update : 1335

84 snips
Sep 26, 2025
Dive into a whirlwind of insights on longevity and health tech! Discover the reality check on rapamycin, revealing its inconsistent benefits for longevity. Learn about new precision approaches to targeting senescent cells with senolytics, ensuring tailored treatments. Explore the promising rise of AI in healthcare while addressing the crucial need for human oversight in diagnosis. Also, find out about federal pilots allowing AI to make Medicare decisions, raising important access concerns. Get actionable tips for a healthier week!
Ask episode
AI Snips
Chapters
Transcript
Episode notes
INSIGHT

Rapamycin Evidence Is Still Unproven

  • A major review finds rapamycin's human longevity evidence weak and inconsistent.
  • Safety concerns mean lifestyle mTOR modulation remains the first-line approach.
ADVICE

Prioritize Lifestyle Before Rapamycin

  • Use lifestyle levers like fasting, protein timing, and smart training to modulate mTOR first.
  • If you try rapamycin, get clinician oversight and track labs pre- and post-use.
INSIGHT

Senescent Cells Are A Diverse 'Zoo'

  • Senescent cells are heterogeneous, so senolytic effectiveness depends on cell subtype and timing.
  • Precision targeting and intermittent dosing will outperform one-size daily approaches.
Get the Snipd Podcast app to discover more snips from this episode
Get the app